Araştırma özeti
Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by
IntroductionEnteric glial cells (EGCs) are key regulators of gut-brain axis immunity, and their excessive activation contributes to intestinal inflammation and neuroimmune disturbances implicated in early Parkinson's disease. Oridonin, a diterpenoid compound with known anti-inflammatory and autophagy-modulating properties, has not been extensively studied in peripheral glial models. Here, we investigated the effects of oridonin on TLR4-mediated inflammatory signaling and autophagy responses in LPS-stimulated EGCs, with molecular docking used as a supportive, hypothesis-generating approach.MethodsRat-derived EGCs were exposed to LPS (10 μg/mL) to induce glial activation. Cells were treated with oridonin (1-5 μM) with or without the selective TLR4 inhibitor TAK-242. mRNA levels of TLR4, S100B, LC3, and beclin-1 were quantified by RT-qPCR, while caspase-1 and IL-1β protein levels were assessed by ELISA. Molecular docking was performed to explore potential interactions of oridonin and TAK-242 with the TLR4 receptor complex.ResultsLPS significantly increased TLR4 and S100B expression and upregulated the autophagy markers beclin-1 and LC3. Oridonin dose-dependently suppressed LPS-induced upregulation of TLR4 and S100B and attenuated the elevation of autophagy-related transcripts. Docking studies suggested that oridonin and TAK-242 may interact with regulatory regions of the TLR4 complex, including surface-exposed sites on the TLR4-MD-2 ectodomain and distinct sub-pockets within the intracellular TIR domain, with oridonin exhibiting a stronger predicted binding affinity. Although LPS increased TLR4 mRNA, it elicited only a modest increase in caspase-1 levels and no significant change in IL-1β levels, consistent with incomplete inflammasome activation. Whereas TAK-242 alone did not fully suppress IL-1β, combined treatment with oridonin reduced cytokine levels more effectively, suggesting complementary downstream modulation rather than direct receptor-level synergy.DiscussionOridonin exerts powerful anti-inflammatory and autophagy-modulating effects in EGCs by inhibiting TLR4-driven signaling, normalizing excessive autophagic responses, and limiting IL-1β output. Its dual capacity to suppress both upstream (TLR4/S100B) and downstream (caspase-1/IL-1β) components of the inflammatory cascade preserves EGC homeostasis under endotoxin stress. These findings highlight oridonin as a potential modulator of peripheral glial inflammation and support further investigation of its therapeutic potential in gut-brain axis disorders.
Bilimsel değerlendirme
Araştırma sorusu
Sorunun kapsamı orijinal çalışma üzerinden değerlendirilir.
Yöntem ve örneklem
Çalışma tasarımı ve örneklem için kaynak makaleyi kontrol edin.
Temel bulgular
Bu kayıt için editoryal olarak onaylanmış bulgu özeti henüz yayımlanmadı.
Sınırlılıklar
Sonuçların genellenebilirliği, yanlılık ve klinik anlamı ayrıca incelenmelidir.
Bibliyografik veriden yöntem, örneklem veya klinik sonuç çıkarımı yapılmaz.